Mayar Capital Ltd. Purchases 19,739 Shares of Solventum Co. (NYSE:SOLV)

Mayar Capital Ltd. raised its stake in Solventum Co. (NYSE:SOLV) by 187.1% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 30,290 shares of the company’s stock after purchasing an additional 19,739 shares during the quarter. Solventum makes up about 2.6% of Mayar Capital Ltd.’s portfolio, making the stock its 10th biggest holding. Mayar Capital Ltd.’s holdings in Solventum were worth $2,001,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds have also bought and sold shares of the company. Modus Advisors LLC bought a new stake in Solventum during the 4th quarter worth $25,000. Stonebridge Financial Group LLC bought a new position in Solventum during the 4th quarter valued at $26,000. True Wealth Design LLC boosted its position in Solventum by 23,550.0% in the third quarter. True Wealth Design LLC now owns 473 shares of the company’s stock worth $33,000 after purchasing an additional 471 shares during the last quarter. Crews Bank & Trust purchased a new stake in Solventum in the fourth quarter worth $32,000. Finally, Prospera Private Wealth LLC bought a new position in Solventum in the 3rd quarter worth about $35,000.

Wall Street Analyst Weigh In

Several analysts have weighed in on SOLV shares. Mizuho boosted their price target on shares of Solventum from $70.00 to $82.00 and gave the stock a “neutral” rating in a research note on Monday, March 3rd. The Goldman Sachs Group boosted their target price on shares of Solventum from $63.00 to $71.00 and gave the company a “sell” rating in a research note on Monday, March 3rd. Bank of America raised their target price on shares of Solventum from $80.00 to $85.00 and gave the stock a “neutral” rating in a research note on Wednesday, February 26th. Morgan Stanley raised their target price on shares of Solventum from $73.00 to $80.00 and gave the company an “equal weight” rating in a research note on Wednesday. Finally, Wells Fargo & Company increased their target price on Solventum from $73.00 to $75.00 and gave the company an “equal weight” rating in a research report on Friday, February 28th. One investment analyst has rated the stock with a sell rating, nine have issued a hold rating and one has assigned a buy rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average target price of $79.86.

Solventum Stock Up 2.9 %

Solventum stock opened at $77.96 on Friday. The company has a debt-to-equity ratio of 2.45, a quick ratio of 0.83 and a current ratio of 1.15. The company has a market capitalization of $13.47 billion and a PE ratio of 28.35. The firm has a 50 day moving average price of $73.65 and a 200 day moving average price of $70.63. Solventum Co. has a fifty-two week low of $47.16 and a fifty-two week high of $85.92.

About Solventum

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.